If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Recognizing early symptoms such as vision changes, weakness, or confusion can be critical. This page explains the symptoms and monitoring guidelines for Tysabri-related PML, building on a long history of patient education about medication risks.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's strongest safety alert, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial and postmarketing surveillance data. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that these factors should be weighed against expected benefits when initiating or continuing therapy. Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication of the disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
PML typically presents with subacute neurological deficits, including cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The condition is often rapidly progressive and can lead to severe disability or death. The FDA Adverse Event Reporting System (FAERS) lists fatigue, multiple sclerosis relapse, headache, gait disturbance, and balance disorder among the most frequently reported adverse events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly confirm PML, they reflect the broad spectrum of neurological symptoms that may overlap with early PML presentation.
The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte adhesion and migration across the blood-brain barrier, Tysabri reduces immune surveillance in the central nervous system. This allows latent JC virus, which is carried by a majority of the population, to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and neuronal damage. The risk is highest in patients with detectable anti-JCV antibodies, as these indicate prior exposure to the virus.
For patients in Ohio who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a product liability claim. In Ohio, the statute of limitations for personal injury claims generally is two years from the date the injury was discovered or reasonably should have been discovered. For PML, the timeline between exposure and documented harm can be variable. Symptoms may emerge months to years after starting Tysabri, and diagnosis often requires specialized testing. The clock for legal action typically starts when the patient or their representative becomes aware of the link between Tysabri and the injury. Given the severity of PML, early consultation with an attorney is advisable to preserve legal rights. The adequacy of warnings regarding Tysabri and PML is a central issue in potential litigation. The FDA boxed warning clearly states the increased risk and identifies known risk factors. However, questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, the need for regular monitoring, and the importance of early discontinuation if symptoms appear. The TOUCH Prescribing Program, a restricted distribution system, was established to ensure that only enrolled patients receive Tysabri and that they are monitored regularly (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, PML cases continue to occur, and affected individuals may seek compensation for medical expenses, lost income, and pain and suffering.
In summary, Tysabri-associated PML is a serious, often fatal condition with well-defined risk factors and a clear mechanistic basis. Patients in Ohio who have been harmed should be aware of the two-year statute of limitations and the importance of timely legal action. The FDA's boxed warning and risk mitigation programs underscore the recognized dangers, but individual cases may still involve questions of warning adequacy and informed consent. If you or a loved one has developed PML after Tysabri treatment, consulting with an experienced attorney can help protect your rights and explore potential compensation.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Ohio, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this typically starts when the patient becomes aware of the link between Tysabri and the injury. It is crucial to consult an attorney promptly to avoid missing the deadline.
Three key risk factors have been identified: presence of anti-JCV antibodies, longer treatment duration (especially over two years), and prior use of immunosuppressants. These factors are outlined in the FDA boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.